Podcasts about clinical trials

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Matthew Laughon, Professor at University of North Carolina and NICHD Neonatal Research Network investigator, presents the landmark PDA Management Trial comparing expectant management versus active medical treatment (indomethacin, ibuprofen, or acetaminophen). The trial stopped early due to futility and safety concerns—mortality exceeded 10% in the treatment group versus 4% with expectant management, with more infection-related deaths among treated infants. Secondary outcomes (BPD, NEC, ROP) showed no differences. The study included infants with symptomatic PDAs but excluded those with severe cardiopulmonary compromise. Findings support expectant management for symptomatic PDAs through 21 days of life, aligning with recent guidelines recommending no routine treatment in the first two weeks. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Shefali Kakar, Global Head of PK Sciences and Oncology at Novartis, returns to the AI in Business podcast to discuss how AI is reshaping the earliest and most critical phases of drug development—where strategic investment decisions are made long before a clinical trial begins. Together with Emerj Editorial Director Matthew DeMello, Shefali explores how advanced modeling, in silico design, and patient data are creating a clearer picture of risk and return across R&D portfolios. She explains how pharmaceutical organizations are leveraging multi-factorial models to simulate safety, efficacy, and market potential—down to the molecular level. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Michael Jordan never won an NBA championship until he was paired with the right coach. Then, he won six. Could working with a coach change your MS journey? In this week's episode, health & wellness coach Amy Behimer explains what health coaching is all about and how working with a coach might impact someone living with MS. We're also sharing study results that show DMTs fail to manage MS-related pain. Then, we'll explain how a common misconception can lead to the wrong outcome for someone with MS. And we'll share study results showing that adhering to the Mediterranean or MIND diet improves cognitive performance among people living with MS. We'll also explain why this study raises as many questions as it seeks to answer. We have a lot to talk about! Are you ready for RealTalk MS??! Thank you!  :22 This Week: What working with a health coach is all about  1:08 Study results show that disease-modifying therapies don't help manage MS-related pain (But are they supposed to???)  2:29 Study results show that adhering to the Mediterranean or MIND diet improves cognitive performance among people with MS (Or does it??)  5:13 Health & Wellness Coach Amy Behimer explains how someone living with MS could benefit from coaching  12:11 Share this episode  39:33 Next week's episode  39:53 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/432 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://www.msard-journal.com/article/S2211-0348(25)00573-5/fulltext STUDY: Mediterranean and MIND Diet Patterns and Cognitive Performance in Multiple Sclerosis: A Cross-Sectional Analysis of the UK Multiple Sclerosis Register https://www.mdpi.com/2072-6643/17/21/3326 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 432 Guests: Amy Behimer Privacy Policy

Date: December 4, 2025 Guest Skeptic: Dr. Jestin Carlson – Long-time listener, second-time guest.   Reference: Reinaud et al. Reporting of Noninferiority Margins on ClinicalTrials.gov: A Systematic Review. JAMA Netw Open. 2025 Case: You are working with a resident who asks you about a new thrombolytic they heard about on the SGEM for acute ischemic stroke.  […] The post SGEM#495: Tell Me Lies, Tell Me Sweet Little Lies – Reporting of Noninferiority Margins on ClinicalTrials.gov. first appeared on The Skeptics Guide to Emergency Medicine.

Prosthetic joint infections (PJI) remain among the most devastating complications in orthopedic surgery, with increasing incidence paralleling the growth in arthroplasty procedures worldwide. While treatment protocols are well-established, evidence supporting current approaches is lacking, and outcomes remain suboptimal, highlighting the need for improved therapeutic strategies. AAC recently published a minireview of randomized controlled trials and emerging evidence for the management for these difficult to treat infection. Today, we discuss with one of the authors of the manuscript and an ID doctor specialized in PJI infections the findings of such paper. Topics discussed: Challenges of treating prosthetic joint infections. Major clinical trial data supporting different approaches for treatment and prevention of PJI Guidance for the approach to these complicated infections. Guests: David Paterson MBBS, Ph.D., Professor, Saw Swee Hock School of Public Health (Joint) Yong Loo Lin School of Public Health (Joint), Director, ADVANCE-ID, National University of Singapore, Singapore.  Ana Victoria Salas-Vargas, M.D. Assistant Professor of Clinical Medicine, Houston Methodist Academic Institute and Weill Cornell Medical College.  This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

A bill that would redraw Indiana's congressional map to benefit Republicans passed through its second reading Thursday after hours of argument. A state-mandated task force chaired by Mayor Joe Hogsett has advanced two proposals that could fundamentally change how Indianapolis schools are governed. Attorney General Todd Rokita and Secretary of State Diego Morales say a federal agency review found 21 noncitizens have cast ballots in Indiana elections, along with 165 noncitizens who registered to vote in the state. Indiana University and Eli Lilly are working together to expand clinical trials. Amazon founder Jeff Bezos and his wife, Lauren Sánchez Bezos, awarded a grant to an Indianapolis nonprofit fighting homelessness. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Zach Bundy, with support from News Director Sarah Neal-Estes.

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

TJ Sharpe is a stage four melanoma survivor, nationally known patient advocate, keynote speaker, digital health technologist, and consultant to the life sciences industry. Drawing from personal experience and his work in clinical research, TJ empowers healthcare and pharma organizations to prioritize patient-centric approaches to trials, communication, and support. He shares his story to inspire others facing adversity and to promote transformative improvements in healthcare. In this episode of Marketer of the Day, TJ Sharpe joins Robert Plank to recount his journey from being diagnosed with melanoma in his twenties, through a life-threatening recurrence that led him to cutting-edge clinical trials, to his eventual recovery and the launch of his advocacy career. TJ details his navigation of the medical system, the emotional and logistical challenges faced by patients, and how gratitude and support systems are as important as medical interventions. The discussion spotlights the importance of accessible, transparent information, and patient empowerment within clinical research. TJ also describes his consulting work to help organizations incorporate patient voices and streamline drug development for the benefit of all. Quotes: “If you don't know all your options, you're not making the most informed choice for you.” “Finding your ‘ninja'—that support person—makes all the difference in getting through a cancer journey.” “It's not just about surviving cancer, it's about making a difference for millions more who will walk this path.” Resources: Visit TJ Sharpe's Website Connect with TJ Sharpe on LinkedIn

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS.  In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR. Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment.  This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct4 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Join Phillip Cuculich, MD and his guests Tina Baykaner, MD, MPH and Atul Verma, MD, FHRS for this lively discussion of a cutting edge topic. The ALONE-AF trial evaluated whether patients who remained free of atrial fibrillation for at least one year after catheter ablation could safely discontinue long-term oral anticoagulation. In this randomized study of more than 800 patients, stopping anticoagulation resulted in similarly low rates of stroke or systemic embolism and significantly fewer major bleeding events compared with continuing therapy. The findings suggest that, in carefully selected post-ablation patients, long-term anticoagulation discontinuation may be a safe and beneficial strategy.   Learning Objectives Evaluate the methodology and patient selection criteria of the ALONE-AF randomized trial to understand which post-ablation patients may be appropriate candidates for long-term anticoagulation discontinuation. Interpret the trial's primary and secondary outcomes to assess the comparative risks of thromboembolism and major bleeding in patients who discontinue versus continue oral anticoagulation after successful AF ablation. Discuss the clinical implications of ALONE-AF for shared decision-making, guideline considerations, and the development of individualized anticoagulation strategies following catheter ablation.   Article Authors Daehoon Kim, MD; Jaemin Shim, MD; Eue-Keun Choi, MD, Il-Young Oh, MD; Jun Kim, MD; Young Soo Lee, MD; Junbeom Park, MD; Jum-Suk Ko, MD; Kyoung-Min Park, MD; Jung-Hoon Sung, MD; Hyung Wook Park, MD; Hyung-Seob Park, MD; Jong-Youn Kim, MD, Ki-Woon Kang, MD; Dongmin Kim, MD; Jin-Kyu Park, MD; Dae-Hyeok Kim, MD; Jin-Bae Kim, MD; Hee Tae Yu, MD; Tae-Hoon Kim, MD; Jae-Sun Uhm, MD; Hui-Nam Pak, MD1; Boyoung Joung, MD; for the ALONE-AF Investigators   Podcast Contributors Tina Baykaner, MD, MPH Phillip Cuculich, MD Atul Verma, MD, FHRS   Article for Discussion

John Abramson, M.D., and Jim Wright, M.D., Ph.D., FRCPC, expose how pharmaceutical industry influence distorts clinical trial outcomes. Gain crucial insights to help you critically evaluate medical evidence and make informed healthcare decisions. #ClinicalTrials #MedicalEthics #PharmaTransparency

Dr. Hoffman continues his conversation with Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes.”

The Revolutionary Role of the Vagus Nerve in Bioelectronic Medicine: Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes,” details the historical context and recent advancements in harnessing the power of the vagus nerve to control inflammation without causing immunosuppression. The conversation explores the journey from early experimental stages to the recent FDA approval for treating rheumatoid arthritis through vagus nerve stimulation (VNS) devices. He also delves into the potential applications of VNS in treating other inflammatory conditions, mood disorders, and the science behind non-invasive lifestyle techniques and commercially available devices. The episode provides valuable insights into the future of bioelectronic medicine and its potential to revolutionize medical treatments.

Send us a textDr. Sara Collins joins Dr. Michael Koren to talk about her journey as a research cardiologist. They discuss Dr. Collins's path through preparatory school, college, med school, and the post-school experience as a cardiologist. They also discuss her role starting a clinical research site in Washington, D.C., and her efforts to leverage the research apparatus to provide equitable care to otherwise disadvantaged and underserved communities. Dr. Collins talks about how there is a racial disconnect in care in spite of the typically good insurance coverage in the D.C. area.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textMethods & challenges of establishing causal relationships in health research, emphasizing epidemiology, randomized trials, and genetic approaches.Topics:Epidemiology: Studies disease influences using observational designs like case-control and prospective cohorts, plus trials, to identify patterns and test hypotheses.Hierarchy of evidence critique: Rejects rigid pyramids favoring RCTs, as all studies can be biased; advocates triangulation integrating varied data types for robust conclusions.RCT strengths & weaknesses: Randomization balances confounders, but issues like poor blinding, attrition, or subversion can undermine results; large samples may yield spurious precision if biased.Confounding & reverse causation: Examples include yellow fingers and lung cancer (both from smoking) or early atherosclerosis inflating CRP-disease links; hard to fully control statistically.Nutrition epidemiology: Observational studies often overstate benefits (e.g., vitamin E for heart disease), leading to failed trials; incentives favor new findings over revisiting errors.Mendelian randomization: Uses genetic variants as proxies for exposures (e.g., ALDH2 for alcohol metabolism) to mimic randomization; reveals no heart benefits from alcohol, unlike observational data.Negative controls: Tests implausible outcomes (e.g., smoking and murder) or exposures (e.g., paternal smoking in pregnancy) to check for confounding artifacts.Evidence triangulation: Combines diverse studies with different biases (e.g., cross-cultural comparisons) for causality; applied to dismiss HDL-raising drugs despite initial promise.Practical Takeaways:Scrutinize health claims by checking for negative controls or variety in evidence sources to avoid mistaking correlation for causation.For personal decisions like alcohol intake, consider genetic studies showing risks at all levels, and aim for moderation or abstinence based on overall evidence.When evaluating supplements or diets, prioritize trials over observational data, and question media hype that ignores confounding factors.About the guest: Dr. George Davey Smith, MD, DSc is a professor of clinical epidemiology at the University of Bristol and director of the MRC Integrative Epidemiology Unit.*Not medical advice.Support the showAffiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

Find More Great Info From Dr. Melanie Matheu Here: SUBSTACK: https://lilscience.substack.com TIKTOK:https://www.tiktok.com/@laughterinlight YOUTUBE: https://www.youtube.com/@LaughterInLight Hawk talks with immunologist Dr. Melanie Matthew about the upcoming flu season and the devastating impact of RFK Jr as HHS Secretary. Australia experienced record-setting influenza deaths this year, with flu killing more people than COVID. The H3N2 variant mutated to evade vaccine protection, leading to unprecedented hospitalizations. Japan declared a flu epidemic five weeks early, and similar patterns are emerging in the United States.Dr. Matthew explains why flu vaccination remains critical despite mutations, reducing hospitalizations by 30-40% in adults and 70-75% in children. The conversation shifts to RFK Jr's anti-vaccine policies at HHS, where he claims no vaccine is safe and effective despite having zero background in immunology or pediatrics. His appointment, along with Marty Makary at FDA and Jay Bhattacharya at NIH, represents a complete rejection of scientific reality in favor of political ideology.The discussion covers RFK Jr's role in 88 child deaths in Samoa from measles, his vitamin A recommendations causing liver damage in Texas children, and how VAERS data is being misrepresented. Dr. Matthew details the exodus of top scientists from NIH, cancelled research grants, and terminated clinical trials that will kill patients. Forever chemicals (PFAS) are being approved for pesticides while vaccine research funding gets slashed.America faces losing measles elimination status, rising preventable disease deaths, and compromised pandemic preparedness. The CDC's COVID vaccine guidance for pregnant women has been offline for months despite evidence linking infection to preterm births and neurological damage. This administration prioritizes grift over public health, with consequences spanning decades. SUPPORT & CONNECT WITH HAWK- Support on Patreon: https://www.patreon.com/mdg650hawk- Support Hawk's Merch Store: https://hawkmerchstore.com- Connect on TikTok: https://www.tiktok.com/@hawkeyewhackamole- Connect on BlueSky: https://bsky.app/profile/mdg650hawk.bsky.social- Connect on YouTube: https://www.youtube.com/@hawkpodcasts ALL HAWK PODCASTS INFO- Additional Podcasts Available Here: https://www.hawkpodcasts.com- Listen to Hawk Podcasts On Your Favorite Platform:Spotify: https://spoti.fi/3RWeJfyApple Podcasts: https://apple.co/422GDuLYouTube: https://youtube.com/@hawkpodcastsiHeartRadio: https://ihr.fm/47vVBdPPandora: https://bit.ly/48COaTBSimplecast: https://hawk-droppings.simplecast.com- Hawk Podcasts RSS Feed: https://feeds.simplecast.com/pPVtxSNJ

In this episode of Dana Tech Talks, Dana Moreau speaks with Anastasia Albanese-O'Neill, Vice President of Medical Affairs at Breakthrough T1D, about the critical role clinical trials play in advancing type 1 diabetes care. They explore emerging therapies, growing screening efforts, and practical tools that help clinicians connect patients to research opportunities. Together, they highlight how building a culture of trial participation can accelerate progress toward T1D cures. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast. Learn more about ADCES and the many benefits of membership at adces.org/join. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Tom Croce, Vice President of Global Patient Advocacy and Engagement at Jazz Pharmaceuticals. Tom shares how his team integrates patient perspectives across the entire drug development and commercialization process, and why “patient centricity” is transforming the pharmaceutical industry. We explore the growing role of patient input in clinical trials, the future of advocacy-driven innovation, and more. Tune in for an insightful discussion on building better treatments by listening to the people who need them most.

Doug Bain, founder and consulting partner of ClinFlo, discusses his proposed regulatory blueprint for digital trials in the latest episode of The Scope of Things podcast. With host Deborah Borfitz, Bain delves into his strategy for turning 21 CFR Part 11 into a more practical regulation that streamlines rather than bogs down clinical trials, what would qualify someone to take on the role as a trusted third party (and what makes them trustworthy), and the new FDA administration's modernization plan aligns—or squares—with his ideas. Plus, the latest news on a tool for detecting fraud and sampling bias in decentralized trials, technology for identifying potentially dangerous drugs before trials start, a novel women's health and menopause initiative, a regenerative therapy for spinal cord injury, and a new oral treatment for preventing dementia. Show Notes :  News Roundup Data collection tools for decentralized trials MyTrials platform study in the Journal of Clinical and Translational Science  Real-time data integration tool Press release on the Mount Sinai website Drug toxicity prediction Article in EbioMedicine  Tufts Women's Health and Menopause Initiative News from Tufts University  Regenerative therapy for spinal cord injury Article in Nature Oral treatment for preventing dementia Press release from Aarhus University  Guest Doug Bain, founder and consulting partner of UK-based ClinFlo  The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Krista Casazza talks about validating key biomarkers in Niemann-Pick type C and why they are essential for future clinical trials and regulatory approval. The discussion focuses on emerging candidates such as 24-hydroxycholesterol, neurofilament light chain, and calbindin-D, alongside the urgent need for data harmonisation and collaboration across the NPC community. Biomarker Validation in NPC1: Foundations for Clinical Trials and Regulatory Alignment Krista Casazza, et al https://doi.org/10.1002/jimd.70075

BrainStorm wants to hear from you! Send us a text.Ep 99: The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer's PlatformIn part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials. Dwyer shares how the field is shifting toward earlier intervention and leveraging artificial intelligence to improve trial efficiency and accuracy. AI can help identify subtle disease patterns and ensure trials enroll appropriate candidates. GAP is also pioneering remote, decentralized trials that bring research into patients' homes rather than requiring frequent clinic visits, aiming to dramatically scale up participation.Dwyer also highlights proven lifestyle interventions that support cognitive health alongside pharmaceutical treatments and suggests multiple treatment approaches may soon be available.This episode of BrainStorm is sponsored by Johnson & JohnsonSupport the show

Ablate before you radiate. Success with bone tumor ablation may have as much to do with your procedure technique as it does with your ability to collaborate. In this episode of BackTable MSK, interventional oncologist Dr. Damian Dupuy shares his approach to bone tumor ablation with host Dr. Kavi Krishnasamy, and offers practical advice on how to partner with your cancer care team to make ablation a viable treatment option. --- This podcast is supported by: Medtronic Osteocool https://www.medtronic.com/en-us/healthcare-professionals/products/surgical-energy/ablation/radiofrequency-ablation/systems/osteocool-2-0-bone-tumor-ablation-system.html --- SYNPOSIS The doctors review the history of bone ablation techniques, including radiofrequency and cryoablation modalities. They discuss the significance of targeting the bone-tumor interface for pain palliation and highlight several case studies to illustrate various techniques and successful outcomes. The conversation also touches upon the synergistic benefits of combining ablation with radiation therapy and emphasizes the importance of multidisciplinary collaboration in treating cancer patients. --- TIMESTAMPS 00:00 - Introduction02:07 - Dr. Dupuy's Start in Bone Ablation06:29 - Cryo vs. Microwave Therapies08:25 - Dr. Dupuy's Clinical Trial and Research Involvement 12:49 - Patient Selection and Treatment Strategies25:54 - Sedation and Anesthesia Practices in Bone Ablation28:46 - Treatment Approach: Oligometastases vs. Progressive Disease36:22 - Microwave Ablation in Bone: Future Prospects37:30 - Techniques for Treating Sclerotic and Lytic Lesions40:01 - Skin Protection Methods in Superficial Lesion Treatments41:49 - Reviewing Recent Clinical Trials: MOTION, OPuS One, and More52:35 - Case Studies: Achieving Effective Ablation Techniques01:08:08 - Final Thoughts and Recommendations --- RESOURCES Dr. Damian E. Dupuy, MD, FACRhttps://www.linkedin.com/in/damian-e-dupuy-md-facr-6b080b1b/ Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network studyhttps://pubmed.ncbi.nlm.nih.gov/23657892/ Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10156864/ Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8011449/ A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy (TRIBUTE)https://clinicaltrials.gov/study/NCT06859801

At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before)  :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old  3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants  4:25 Dr. Kristen Krysko discusses MS and women's health issues  7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy  13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14  16:55 Share this episode  33:20 Next week's episode  33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy

Send us a textDr. Michael Koren joins Kevin Geddings to share an anecdote; an acquaintance seemed to put trust in Mel Gibson on a podcast over the American healthcare system. The doctor analyzes why there has been an erosion of trust in this system, why institutions like the medical community and clinical research should be trusted, and how participating in clinical trials can increase your trust in the system as a whole. Dr. Koren also challenges listeners with a specific healthcare biomarker that may be putting your heart at risk.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr Michael Lanspa chats with Dr. Imeen van der Wal and Dr. Chloe Grim on their article, "Conservative versus Liberal Oxygenation Targets in Intensive Care Unit Patients (ICONIC): A Randomized Clinical Trial." 

Drs. Lewiecki and Camacho discuss sequential therapy in osteoporosis as a critical strategy that involves strategically switching between anabolic and antiresorptive treatments to maximize bone mineral density and reduce fracture risk. By carefully transitioning between different drug classes (eg, romosozumab; teriparatide; denosumab), clinicians can optimize patient outcomes and address the evolving needs of individuals with bone health challenges.

Send us a textDermatologist and clinical researcher Dr. Michael Bernhardt joins Dr. Erich Schramm to unpack the rapidly evolving science of atopic dermatitis. The two doctors discuss the symptoms, science, and treatments for atopic dermatitis, including how much clinical research has changed the landscape and improved outcomes. The two get into how the immune system drives the disease, and how new therapeutic drugs target those systems in way thats more than just skin deep.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, I'm joined by Dr. Brad Currier, Manager of Clinical Trials at Timeline Nutrition and an expert in the world of muscle and aging research. Brad is on the cutting edge of mitochondrial science, and in this episode, he helps us unravel the mysteries of why some 80-year-olds are still crushing it in the gym while others struggle to get up the stairs. We dive into his fascinating research on mitophagy—our bodies' system for recycling dysfunctional mitochondria—and what it means for muscle health, strength, and vibrant aging.   Visit Timeline.com/nat20 and use code nat20 for 20% off your purchase.   Episode Timestamps: Episode start … 00:00:00 What is Mitophagy? Why It Matters as We Age ... 00:04:53 Mitophagy in Athletes vs. General Population ... 00:07:15 Urolithin A and Why Most People Can't Make It ... 00:12:12 What Mitopure Does: Mitophagy and Biogenesis ... 00:24:10 Key Study: Strength Gains in Middle-Aged Adults ... 00:26:43 Dose Guidance: 500mg vs. 1g ... 00:31:39 Anti-Inflammatory Effects and Immune Health ... 00:33:07 Benefits Beyond Muscle: Skin, Immunity, Brain ... 00:35:01 Weightlifter Study: Performance in Trained Athletes ... 00:40:34 Mitopure for Recovery and User Experiences ... 00:46:41 How to Use Mitopure: Timing, Dosage, Consistency ... 00:52:54 Protein, Creatine, and Mitopure: The Basics Stack ... 00:53:41 Recovery, Cycling, and How Soon Benefits Appear ... 00:58:44 Debunking Myths: Pomegranate, Antioxidant, Athletes Only ... 01:10:26 Mitopure vs. Generic Urolithin A: Safety Concerns ... 01:13:39   Our Amazing Sponsors: Tranq Dart by Wizard Sciences - a multi-pathway sleep support from Wizard Sciences. It's not a knockout pill; it's a gentle nudge toward that wind-down zone. I take it about 30 minutes before bed, and it helps my body and brain sync up for sleep. Visit wizardsciences.com and use code NAT15 for 15% off. Sleep smarter, not harder.   Tro Mune by Troscriptions - Cold season doesn't have to take you out. I use Tro Mune—a nightly buccal troche with 75 mg cordycepin—to build immune resilience while I sleep. Take ½–1 before bed, and use it before you get sick or right when you feel it. Troscriptions.com, use NAT10, and get 10% off your first order.   Thymus & Pineal BioRegulators - The Thymus Bioregulator helps keep immune response balanced and small human studies in older adults link it with healthier immune markers and fewer seasonal respiratory issues. The Pineal Bioregulator supports your natural melatonin/circadian rhythm—key when schedules and daylight change—so you get the kind of sleep that underpins immune resilience. Head to profound-health.com and use code LONGEVITY15 for 15% off your first order.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________We open with community member MiMi, who shares her experience participating in an Eli Lilly Retatrutide clinical trial, offering a rare, real-world look at this next-generation triple-agonist research. From there, we dive into how menopause and perimenopause reshape metabolism with insight from Dr. Komal Patil-Sisodia, an endocrinologist, obesity-medicine specialist, and midlife menopause expert. We explore how HRT and GLP-1 medications support symptoms, weight, and long-term health, what early research suggests about combining them, and why bone density, TMJ, and diabetes risk all matter in midlife care.Follow Mimimimi_in_australiaFollow Dr. Patil drpatilsisodia______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Send us a textDr. Michael Koren joins Kevin Geddings to give thanks this week. The doctor gives gratitude to Kevin, his team, clinical research staff, MedEvidence staff, and most of all, patients. Dr. Koren expresses his heartfelt thanks to everyone who pushes science and research forward!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Sabine Hazan is a pioneering gastroenterologist and the first physician to launch a private microbiome testing lab in the U.S. In this powerful episode, she reveals how decades of clinical experience and cutting-edge research have convinced her that the gut microbiome—especially the near-extinction of key bacteria like Bifidobacteria—lies at the root of Autism, Alzheimer's, cancer, and many chronic diseases. Speaking candidly about the erosion of the doctor-patient relationship, relentless censorship, and the profit-driven forces that have turned medicine into a pill-pushing machine, Dr. Hazan explains why she believes the art of medicine is dying—and how restoring the microbiome could bring it back to lifeProgenabiome: https://progenabiome.comClinical Trials: https://progenabiome.com/clinical-trialsX: https://x.com/SabinehazanMDChroma Light Devices, use "BFCM2025" for 21% discount at https://getchroma.co/?ref=autismUse "autism"$50 discount https://buy.daylightcomputer.com/autism10% discount https://figtreegolf.com/?ref=autismhttps://thecognity.com0:00 Chroma, use "BFCM2025"; Daylight Computer & Fig Tree Golf, use "autism"2:00 Dr. Sabine Hazan; Gastroenterologist; Microbiome; Fecal Transplant; Covid, Alzheimers, Cancer, Gut Conditions7:12 The Impact of COVID on Medical Perspectives; Censorship & Narratives12:26 The Art of Medicine & Relationships- more than just pills (Big Harma)16:28 Understanding Autism & Microbiome connections; Cancer21:16 Challenges with Clinical Trials & Funding26:58 Innovations in Treatment versus the Status Quo31:44 Censorship & Narrative Control (Profits over Humanity); Dr. Andy Wakefield & Autism35:52 The Role of Vaccines & Antibiotics40:16 Future of Microbiome Research & Treatment; Bifidobacteria47:52 Preserving the Microbiome; Mother's & Autism; Autism Research54:18 Fighting Censorship in Science; Narrative Control1:00:56 Lab Testing for Autism; Red Light; Dr. Jack Kruse1:09:14 Collaborating versus Censorship1:13:03 Humanity & Health; Profits over Humanity1:17:27 The Medical Oath; Urgency in Microbiome & BifidobacteriaX: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

Overview Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science. Early Themes: Injury, OCD, and Choosing Psychiatry Early in the episode, Evelyn Eddy Shoop PMHNP-BC describes how multiple season ending injuries in college and serious mental health stressors in her family pushed her to rethink her life path. Originally pre vet, she stepped away from veterinary medicine after realizing she could not tolerate that environment. During a semester off for surgery and mental health, she completed intensive outpatient treatment and family therapy. That time showed her how powerful psychological work could be. It also reawakened a long standing curiosity about the brain, consciousness, and human experience. This led her to switch her major to psychology and later pursue psychiatric mental health nurse practitioner training at the University of Pennsylvania. At Penn, she felt supported academically and personally. Her interest in psychedelics grew as she realized that standard OCD treatments and high dose SSRIs were not giving her the level of functioning or happiness she knew was possible. Core Insights: Psilocybin Trials, Qualitative Data, and Clinical Skepticism In the middle of the episode, Eddy shares the story of finding a psilocybin trial on ClinicalTrials.gov just as she was about to start ketamine therapy. She received placebo first, then open label psilocybin, and describes the dosing day as one of the hardest days of her life, with benefits that emerged slowly over months through integration. She uses her experience to highlight why qualitative data matters. Numbers alone cannot capture the depth of a psychedelic journey or the slow unfolding of meaning over time. She argues that subjective stories, even difficult ones, are essential for clinicians, researchers, and policymakers. Key themes include: The central role of integration support in turning a crisis level session into lasting growth How trial environments on inpatient psychiatric units can feel like prison instead of healing spaces The limits of double blind placebo trials when participants become desperate for active treatment The need for more nuanced language around psychosis and psychedelic harms Eddy also addresses skepticism in psychiatry. Many providers fear substance induced psychosis and feel uneasy with medicines whose mechanisms are not fully understood. She suggests that more lived experience stories and careful education can help bridge that gap. Later Discussion and Takeaways In the later part of the episode, Eddy and Joe discuss harm reduction, ketamine risks, and how poorly designed systems can create harm even when the medicine itself is helpful. Eddy describes being treated as "just another psych patient" once the research team left for the day, including being denied basic comforts like headache relief after an emotionally intense session. She calls for: More humane hospital and research environments Required psychedelic education in psychiatric training Honest, nonjudgmental conversations about substance use with patients Stronger public education for students and festival communities Eddy also invites listeners in Wilmington, Delaware and nearby regions to connect if they need a psychiatric mental health nurse practitioner for psychedelic related research. She hopes to bring her lived experience and clinical skills into the emerging field as psilocybin and other treatments move toward approval. Frequently Asked Questions Who is Evelyn Eddy Shoop PMHNP-BC? She is a psychiatric mental health nurse practitioner trained at the University of Pennsylvania, a former Division I athlete, and a psilocybin trial participant who now advocates for more humane and data informed psychedelic care. What did Eddy learn from her psilocybin clinical trial experience? She learned that the hardest sessions can lead to deep change when integration support is strong and when there is time to unpack insights, rather than rushing to rate symptoms on a scale. Why does she care so much about qualitative data in psychedelic research? Eddy believes that numbers cannot capture the full human impact of psychedelic therapy. Stories show how people actually live with their disorders and integrate change, which is vital for ethical practice and policy. How does she view psychedelic harms and psychosis risk? She acknowledges real risks, especially for people with certain histories, but also notes that some psychotic experiences are not distressing. She calls for more precise language, better containers, and honest harm reduction education. What role does a psychiatric nurse practitioner like Evelyn play in psychedelic care? Practitioners like Evelyn can assess risk, prescribe within legal frameworks, provide preparation and integration, and help bridge the gap between traditional psychiatry and emerging psychedelic therapies. Psychedelic care is evolving fast, and this episode shows why voices like Evelyn Eddy Shoop PMHNP-BC are essential in the current psychedelic resurgence. Her blend of lived experience, clinical training, and critical thinking points toward a future where data and story, safety and possibility, can finally grow together.

Program notes:1:25 mRNA flu vaccine2:25 Phase three trial3:25 Preventing infection with a respiratory virus4:25 Prophylaxis with NSAID?4:45 Umbrella review of acetaminophen in pregnancy, ASD and ADHD5:42 Confidence was low to critically low6:45 Other factors such as environmental exposures7:22 Increasing potassium to prevent heart arrythmias8:33 Increase with supplements or dietary advice9:18 Canceling funding for clinical trials10:18 In the process of receiving interventions11:18 Can't not analyze 12:15 End

If you're interested in optimising your healthspan and lifespan, this episode is not to be missed. In the quest for longevity, the spotlight has turned to NAD+ and its precursors, NMN and NR. In this episode featuring Dr. Charles Brenner, a metabolism scientist, we dive deep into the significance of these molecules and their role in healthy aging. You'll discover that NAD+ (Nicotinamide Adenine Dinucleotide) is not just a trending topic but rather a crucial player in metabolism. Learn why Charles refers to it as the "central jewel of metabolism". In the conversation, the distinction between NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) is clarified, and you'll discover which of these molecules has the best evidence-base. You'll also find out why some popular ways to increase NAD+ are an expensive waste of time. Dr. Brenner highlights the importance of evidence-based research, citing eight randomised clinical trials demonstrating the anti-inflammatory effects of one of the NAD+ precursors in humans. One significant study focuses on peripheral artery disease (PAD), a condition affecting millions of older adults that can severely impact mobility and quality of life. Ypu'll also disciver why a simple functional test is a way better predictor of longevity than all of the espoensive epigenetic-focused Biological Age tests that are currently on the market. What You'll Learn: The Basics of NAD and Its Functions: Understand the foundational role of NAD in cellular metabolism and how it acts as a transmitter of high-energy electrons needed for energy production and cell functions. Scientific Evidence and Research: Discover the rigor behind the clinical research of NAD and its supplements, like Nicotinamide Riboside (NR), including ongoing trials and results showing anti-inflammatory properties in humans. Controversies and Misconceptions: Unpack the myths concerning longevity molecules, such as misinterpretations around resveratrol, with arguments laid out by reputable scientists like Dr. Brenner. Applications in Age-Related Diseases: Explore the potential of NR supplements in addressing conditions like peripheral artery disease and its promising though variable outcomes in treating Long COVID and neurodegenerative diseases. Critical Analysis of Clinical Trials: Learn about the importance of clinical integrity, unbiased research, and how independent laboratories contribute to credible scientific discoveries. Key Takeaways: NAD is vital for maintaining metabolic health and managing cellular stress, which is essential for healthy aging. Recent clinical trials have shown promising results for NR in reducing inflammation and improving conditions related to peripheral artery disease. There's ongoing research into NR's benefits for cognitive function, particularly its potential effects on neurodegenerative disease. Supplements should be chosen carefully, preferably ones that have been tested in clinical trials to ensure efficacy and authenticity. The conversation between Dr. Taylor and Dr. Brenner highlights the need to critically evaluate scientific claims, especially those that are widely publicised without robust evidence. Through the episode, Dr. Brenner provides deep insights into how NAD coenzymes operate within the body and why they're considered crucial for longevity research. Moreover, listeners are encouraged to discern meticulously between scientific fact and internet hype, ensuring they make informed decisions when considering supplements. The episode is a valuable resource for anyone interested in the intersection of biochemistry, aging, and healthspan science. Resources Socials: X: @CharlesMBrenner LinkedIn: https://www.linkedin.com/in/charles-brenner/ Support the Podcast If you found this conversation valuable, consider subscribing and leaving a review on your preferred podcast platform. Your feedback helps us continue to bring you insightful discussions on important health topics. 00:11 Understanding NAD+ and Longevity Molecules 01:31 Debunking Longevity Myths 03:02 The Science Behind NAD+ and Metabolism 08:46 Clinical Trials and Evidence 09:37 Peripheral Artery Disease and NAD+ 11:00 Walking Speed as a Health Indicator 13:25 Challenges with DNA Methylation Clocks 21:40 NAD+ in Metabolic Processes 23:48 The Role of NAD in DNA Repair and Cellular Health 24:09 Inflammation and Aging: The Connection 25:20 Human Longevity and Reproductive Capacity 30:02 The Hallmarks of Aging 31:11 Challenges of Living in 2025: Long COVID 31:42 Clinical Trials and NAD Supplements 34:33 The Debate on NMN vs. NR 41:58 Intravenous NAD and Its Efficacy 45:06 NAD's Role in Neurodegenerative Diseases See omnystudio.com/listener for privacy information.

Robert's LinkedIn: https://www.linkedin.com/in/robert-s-goldman/Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join host and HRS Digital Education Committee Member Melissa Middeldorp, MPH, PhD and her guests Rod Passman, MD, FHRS, and Emma Svenberg, MD, PhD, live at HRX 2025. In this episode, we explore the AMALFI Randomized Clinical Trial, which evaluated whether remote, wearable-based screening can effectively detect asymptomatic atrial fibrillation in high-risk adults. The discussion breaks down the study design, key findings, and implications for population-level AF screening strategies. It also examines how emerging digital health tools may integrate into routine cardiovascular prevention.    Learning Objectives Describe the design, patient population, and primary outcomes of the AMALFI Randomized Clinical Trial. Evaluate the effectiveness of remote wearable monitoring compared with usual care for detecting asymptomatic atrial fibrillation. Discuss the potential clinical and health-system implications of implementing large-scale remote AF screening in high-risk populations.   Article Authors Rohan Wijesurendra, DPhil, Guilherme Pessoa-Amorim, DPhil, Georgina Buck, MSc,Charlie Harper, DPhil, Richard Bulbulia, MD, Alison Offer, PhD, Nicholas R. Jones, DPhil, Christine A'Court, MA, Rijo Kurien, MSc, Karen Taylor, MSc, Barbara Casadei, DPhil, Louise Bowman, MD.   Podcast Contributors Melissa E. Middeldorp, MPH, PhD Rod S. Passman, MD, FHRS Emma Svennberg, MD, PhD   Article for Discussion  

If you've been looking for a smart, scalable, low-lift revenue stream to add to your pharmacy—this session is absolutely worth your time. Independent pharmacies are perfectly positioned to support clinical trial recruitment, yet most have never been invited to participate. SiteLabs is changing that. In this session, Paige and Darren break down exactly how you can plug into a nationwide colorectal cancer clinical trial and earn $140–$200 per qualified patient enrollment, all while improving patient care in your community.   **Show Notes:** 1. **Introduction** [0:00] 2. **Overview of Site Labs and Clinical Trial Program** [6:30] 3. **Details of the Clinical Trial Program** [15:50] 4. **Q&A and Additional Information* [21:57]     ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We open with community member MiMi, who shares her experience participating in an Eli Lilly Retatrutide clinical trial, offering a rare, real-world look at this next-generation triple-agonist research. From there, we dive into how menopause and perimenopause reshape metabolism with insight from Dr. Komal Patil-Sisodia, an endocrinologist, obesity-medicine specialist, and midlife menopause expert. We explore how HRT and GLP-1 medications support symptoms, weight, and long-term health, what early research suggests about combining them, and why bone density, TMJ, and diabetes risk all matter in midlife care.Follow Mimimimi_in_australiaFollow Dr. Patil drpatilsisodiaSend us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

The FDA belatedly liberates women's hormone replacement; Beta-blockers now deemed passé for routine heart attack aftercare; After most breast cancer surgery, adjuvant radiation brings no survival benefits; Can you drink caffeinated coffee if you have atrial fibrillation? Ignore frequent falls without attention to balance and stability training at your peril; Is it reasonable to contemplate a knee replacement surgery at 88? 

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:  Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information

In this Huberman Lab Essentials episode, my guest is Dr. Jack Feldman, PhD, a Distinguished Professor of Neurobiology at the University of California, Los Angeles, and a leading expert in the science of breathing. We explain the mechanics of breathing and the neural circuits that generate and regulate our breathing rhythm. We also discuss how breathing patterns profoundly influence mental states, including their role in reducing anxiety and enhancing emotional resilience. Dr. Feldman also shares practical tools, such as box breathing for daily performance and magnesium L-threonate supplementation to support cognitive health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Mateina: https://drinkmateina.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps 00:00:00 Jack Feldman 00:00:23 Breathing Mechanics, Diaphragm; Pre-Bötzinger Complex & Breath Initiation 00:03:25 Nose vs Mouth Breathing 00:04:23 Sponsor: Mateina 00:05:24 Active Expiration & Brain; Retrotrapezoid Nucleus 00:08:32 Diaphragm & Evolution; Lung Surface Area & Alveoli, Oxygen Exchange 00:12:56 Diaphragmatic vs Non-Diaphragmatic Breathing 00:14:23 Physiological Sighs: Frequency & Function; Polio & Ventilators 00:18:21 Sponsor: AGZ by AG1 00:19:52 Drug Overdose, Death & Gasps 00:21:38 Meditation, Slow Breathing & Fear Conditioning Study 00:25:28 Mechanistic Science in Breathwork Validation; Breath Practice & Reduced Fear 00:27:21 Breathing & Emotional/Cognitive State, Olfaction, Vagus Nerve 00:29:44 Carbon Dioxide, Hyperventilation & Anxiety 00:31:21 Sponsor: Eight Sleep 00:32:47 Breathing, Emotion & Autonomic Processes Coordination; Depression & Breath Practices 00:36:43 Tool: Breathwork Practices, Box Breathing, Tummo, Wim Hof 00:38:46 Magnesium L-Threonate & Cognitive Enhancement; Compound Refinement 00:44:28 Clinical Trial, Magnesium L-Threonate & Cognitive Improvements; Dose, Sleep 00:48:28 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this fascinating episode, Dr. Gabrielle Lyon talks with neuroscientist Dr. Ben Rein, PhD (author of Why Brains Need Friends), about the science of social connection, emotion, and cognitive health. Dr. Rein, an expert in neurobiology and psychedelic research, reveals the cutting-edge studies that explain why loneliness is as damaging as smoking and how our digital world is affecting our brain's ability to connect.They discuss the neurochemistry of love, the controversial use of MDMA in therapy, and whether AI can ever truly replace human intimacy. This conversation provides an essential look at the biological drivers of happiness, performance, and long-term brain health.Chapter Markers:0:00 - MDMA (Molly): The History & Therapeutic Benefits 5:59 - The Legal Status of MDMA for PTSD 6:44 - The Safety and Effectiveness of MDMA in Clinical Trials 8:29 - PTSD (The Amygdala Alarm) 9:41 - How MDMA Soothes the Amygdala to Access Memory 11:42 - Is There an Alternative to MDMA? (Ketamine's Mechanism) 13:16 - Ketamine and Neuroplasticity for Depression 15:48 - Botox and Empathy: 18:12 - The Problem of Volume: How Screens Depersonalize Interaction 19:48 - The Virtual Disengagement Hypothesis Explained 25:00 - Defining Cognitive and Emotional Empathy 29:43 - MDMA's Link to Serotonin & Social Reward 31:04 - Do SSRIs Have Pro-Social Effects? 36:10 - The Science of Likability and "Easy to Read" Faces 40:10 - Top 3 Ways to Be More Likable49:49 - The Likability Gap: Why You Underestimate How Well-Liked You Are 56:59 - The Neurobiology of Oxytocin, Dopamine, and Serotonin1:09:23 - The Goldilocks Zone of Empathy 1:15:58 - Narcolepsy 1:18:16 - Alcohol: Why the Neurotoxin is Bad for Brain Health 1:21:47 - Exercise and Neurogenesis1:22:27 - Sex, Orgasm, and Oxytocin Release 1:25:06 - Oxytocin During Childbirth Who is Ben Rein:Dr. Ben Rein is an award-winning neuroscientist and Chief Science Officer of the Mind Science Foundation, where he supports early-career researchers in neuroscience. He earned his PhD from SUNY Buffalo and completed postdoctoral training at Stanford University, publishing over 20 peer-reviewed papers on autism, empathy, MDMA, and digital behavior. Recognized by the NIH, the Society for Neuroscience, and Sigma Xi, he also serves as a scientific advisor to more than 20 organizations. With over one million followers and 75 million video views, Dr. Rein is celebrated for making neuroscience accessible to the public and has been featured by outlets such as Good Morning America, ABC News, and PopularMechanics.Thank you to our sponsors:BodyHealth: Use code LYON20 to get 20% off your first order https://www.bodyhealthaffiliates.com/73L4QL3/7XDN2/BON CHARGE Holiday Sale https://boncharge.com for 25% off Pique 20% off for life: https://Piquelife.com/DRLYONFind Ben Rein at: Website: https://www.benrein.com/Instagram: https://www.instagram.com/dr.benrein/#TikTok: https://www.tiktok.com/@dr.benrein?lang=enFacebook:

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.